First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$34.38−$1.45 (−4.06%) on the dayAs of the close; data may be delayed.
TRAX price, last 12 months
Key stats
- Previous close
- $35.83
- Open
- $35.82
- Day range
- $33.66 – $35.82
- 52-week range
- $14.72 – $49.91
- Volume
- 293.5K
- Avg volume (20 days)
- 731.2K
- Market cap
- $1.2B
Performance
1W−11.0%
1M−22.2%
3M+114.4%
6M—
YTD—
1Y—
Technicals and fundamentals
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.2B